Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $180.00 short call and a strike $185.00 long call offers a potential 26.58% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $180.00 by expiration. The full premium credit of $1.05 would be kept by the premium seller. The risk of $3.95 would be incurred if the stock rose above the $185.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 26.13 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why
Mon, 06 May 2019 20:15:57 +0000
Esperion popped Monday after the Food and Drug Administration accepted its applications for a pair of cholesterol treatments called bempedoic acid and bempedoic acid plus ezetimibe.
Migraine drugs cause pain for investors
Fri, 03 May 2019 19:18:05 +0000
CNBC's Meg Tirrell reports on a group of migraine drug manufacturers that missed expectations on earnings.
Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down
Fri, 03 May 2019 12:42:12 +0000
Ligand (LGND) first-quarter earnings and sales decrease year over year.
The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen
Fri, 03 May 2019 11:49:09 +0000
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: …
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
Fri, 03 May 2019 10:28:10 +0000
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Also on Market Tamer…
Follow Us on Facebook